Karyopharm Therapeutics Inc. Contracts & Agreements

Sixth Amendment to Lease, dated November 5, 2024, by and between the Company and TCD 234 MA WELLS PROPERTY LLC (Filed With SEC on November 8, 2024)

Transition Agreement, dated as of August 29, 2024, between the Company and Michael Mason (Filed With SEC on August 29, 2024)

Consulting Agreement, dated as of August 29, 2024, between the Company and Michael Mason (Filed With SEC on August 29, 2024)

Non-Employee Director Compensation Policy (Filed With SEC on May 8, 2024)

Offer Letter, dated as of April 4, 2022, between the Registrant and Reshma Rangwala (Filed With SEC on May 8, 2024)

Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on February 29, 2024)

Common Stock Purchase Warrant, dated August 1, 2023, issued to Heathcare Royalty Partners III, L.P (Filed With SEC on August 2, 2023)

Second Amendment to Revenue Interest Financing Agreement, dated as of August 1, 2023, by and among the Registrant, Karyopharm Europe GmbH, HealthCare Royalty Partners III, L.P.,... (Filed With SEC on August 2, 2023)

Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 2, 2023)

Form of Restricted Stock Unit Agreement (Performance Vested) under 2022 Equity Incentive Plan (Filed With SEC on February 15, 2023)

Form of Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement (Filed With SEC on December 5, 2022)

Securities Purchase Agreement, dated December 5, 2022, by and among the Company and the other parties thereto (Filed With SEC on December 5, 2022)

Registration Rights Agreement, dated December 5, 2022, by and among the Company and the other parties thereto (Filed With SEC on December 5, 2022)

Form of Incentive Stock Option Agreement under 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)

Form of Restricted Stock Unit Agreement under 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)

Form of Incentive Stock Option Agreement under the 2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)

Form of Restricted Stock Unit Agreement under the 2022 Israel Equity Incentive Sub Plan to the 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)

Non-Employee Director Compensation Policy dated June 30, 2022 (Filed With SEC on August 4, 2022)

Severance agreement, dated August 2, 2022, between the Registrant and Ran Frenkel (Filed With SEC on August 4, 2022)

Consulting Agreement, dated August 2, 2022, between the Registrant and Ran Frenkel (Filed With SEC on August 4, 2022)

Severance Agreement, dated February 18, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)

Consulting Agreement, dated March 1, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)

Amendment #1 to Consulting Agreement, dated March 21, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)

Side Letter to Offer Letter, dated October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on May 5, 2022)

Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Filed With SEC on March 29, 2022)

Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Filed With SEC on March 29, 2022)

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted January 24, 2022 (Filed With SEC on March 1, 2022)

2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)

Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)

Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)

License Agreement, dated as of December 17, 2021, between the Registrant and Berlin-Chemie AG (Menarini Group) (Filed With SEC on March 1, 2022)

Amendment to Asset Purchase Agreement, dated as of July 17, 2019, by and between the Registrant and Biogen MA Inc (Filed With SEC on November 3, 2021)

Non-Employee Director Compensation Policy, dated as of May 12, 2021 (Filed With SEC on August 5, 2021)

Omnibus Amendment to Transaction Documents, dated as of June 23, 2021, by and among the Company, Karyopharm Europe GmbH, Karyopharm Therapeutics (Bermuda) Ltd., HealthCare Royalty... (Filed With SEC on June 24, 2021)

Offer Letter, dated as of April 28, 2021, between the Company and Richard Paulson (Filed With SEC on May 3, 2021)

Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on May 3, 2021)

Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on May 3, 2021)

Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 24, 2021)

Fifth Amendment to Lease, dated as of August 13, 2020, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC (Filed With SEC on November 2, 2020)

Letter Agreement, dated as of October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on November 2, 2020)

Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)

Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)

Form of Nonstatutory Stock Option Agreement for Inducement Grants adopted August 25, 2020 (Filed With SEC on November 2, 2020)

2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)

Form of Option Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)

Form of Restricted Stock Unit Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)

Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)

Consulting Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)

Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on August 31, 2020)

Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on August 31, 2020)

Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Christopher B. Primiano (Filed With SEC on August 31, 2020)

Letter Agreement, dated as of August 31, 2020, between the Company and Michael Mason (Filed With SEC on August 31, 2020)

Amendment to License Agreement, dated May 1, 2020, by and between Antengene Therapeutics Limited and the Registrant (Filed With SEC on August 4, 2020)

Amendment No. 1 to the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated May 5, 2020 (Filed With SEC on May 5, 2020)

Underwriting Agreement, dated March 3, 2020, by and among the Company, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC (Filed With SEC on March 4, 2020)

Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)

Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P (Filed With SEC on November 4, 2019)

Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 6, 2019)

Offer Letter, dated February 3, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)

Nonstatutory Stock Option Agreement, dated February 25, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)

Separation Agreement dated January 17, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)

Consulting Agreement dated January 18, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)

Retention Agreement dated January 17, 2019, between the Company and Cameron Peters (Filed With SEC on January 18, 2019)

Indenture (including form of Note) with respect to the Companys 3.00% convertible senior notes due 2025, dated as of October 16, 2018, between the Company and Wilmington Trust,... (Filed With SEC on October 16, 2018)

Open Market Sale AgreementSM, dated August 17, 2018, by and between Karyopharm Therapeutics Inc. and Jefferies LLC (Filed With SEC on August 17, 2018)

License Agreement, dated May 23, 2018, by and between Antengene Therapeutics Limited and the Registrant (Filed With SEC on August 7, 2018)

Parent Company Guarantee, dated May 23, 2018, by Antengene Corporation Co. Ltd (Filed With SEC on August 7, 2018)

Fourth Amendment to Lease, dated June 6, 2018, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC and the Registrant (Filed With SEC on August 7, 2018)

Offer Letter, dated June 7, 2018, by and between the Registrant and Anand Varadan (Filed With SEC on August 7, 2018)

Asset Purchase Agreement, dated January 24, 2018, by and between Biogen MA Inc. and the Registrant (Filed With SEC on May 10, 2018)

Third Amendment to Lease, dated February 28, 2018, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC (Filed With SEC on May 10, 2018)

Form of Nonstatutory Stock Option Agreement for Inducement Grants (Filed With SEC on May 10, 2018)

Underwriting Agreement, dated May 2, 2018, by and among the Company, J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC (Filed With SEC on May 3, 2018)

License Agreement, dated October 11, 2017, by and between the Registrant and Ono Pharmaceutical Co., Ltd (Filed With SEC on March 15, 2018)

Amendment No. 2 to Controlled Equity OfferingSM Sales Agreement, dated December 7, 2015, as amended on November 7, 2016, by and between the Company and Cantor Fitzgerald & Co.,... (Filed With SEC on December 1, 2017)

Offer Letter, dated September 9, 2017, between the Company and Michael Falvey (Filed With SEC on September 12, 2017)

Nonstatutory Stock Option Agreement, dated September 11, 2017, between the Company and Mr. Falvey (Filed With SEC on September 12, 2017)

KARYOPHARM THERAPEUTICS INC. (aDelaware corporation) 3,902,439 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 26, 2017)

CONSULTING AGREEMENT (Filed With SEC on April 3, 2017)

First Amendment to Letter Agreement (Filed With SEC on March 16, 2017)

KARYOPHARM THERAPEUTICS INC. CONTROLLED EQUITY OFFERINGSM AMENDMENT NO. 1 TO SALES AGREEMENT (Filed With SEC on November 8, 2016)

KARYOPHARM THERAPEUTICS INC. Shares of Common Stock (par value$0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on December 8, 2015)

KARYOPHARM THERAPEUTICS INC. RESTRICTED STOCK UNIT AGREEMENT (Filed With SEC on November 9, 2015)

KARYOPHARM THERAPEUTICS INC. (Filed With SEC on November 9, 2015)

1. Nachtrag zum Geschäftsführer- Anstellungsvertrag (Filed With SEC on November 9, 2015)

FIRST AMENDMENT TO CONSULTING AGREEMENT BETWEEN KARYOPHARMTHERAPEUTICS AND MIRZA CONSULTING (Filed With SEC on November 9, 2015)

SECOND AMENDMENT TO LEASE (Filed With SEC on November 9, 2015)

Geschäftsführer-Anstellungsvertrag zwischen (Filed With SEC on March 13, 2015)

Page 2 of 6 (Filed With SEC on March 13, 2015)

KARYOPHARM THERAPEUTICS INC. (Filed With SEC on March 13, 2015)

Vereinbarung über die Änderung eines Geschäftsführer-Anstellungsvertrags (Filed With SEC on March 13, 2015)

KARYOPHARM THERAPEUTICS INC. (Filed With SEC on January 23, 2015)

KARYOPHARM THERAPEUTICS INC. (aDelaware corporation) 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 8, 2015)

FIRST AMENDMENT TO LEASE (Filed With SEC on January 5, 2015)

[Signatures appear on following page] (Filed With SEC on August 8, 2014)

CONSULTING AGREEMENT (Filed With SEC on August 8, 2014)

KARYOPHARM THERAPEUTICS INC. (a Delaware corporation) [ ] Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 25, 2014)

OFFICE LEASE AGREEMENT BETWEEN NS WELLS ACQUISITION LLC, a Delaware limited liability company (LANDLORD) AND KARYOPHARM THERAPEUTICS INC., a Delaware corporation (TENANT) (Filed With SEC on April 1, 2014)

KARYOPHARM THERAPEUTICS INC. (Filed With SEC on March 21, 2014)

KARYOPHARM THERAPEUTICS INC. (a Delaware corporation) Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 28, 2013)

KARYOPHARM THERAPEUTICS INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on October 28, 2013)

KARYOPHARM THERAPEUTICS INC. INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on October 28, 2013)

KARYOPHARM THERAPEUTICS INC. NONSTATUTORY STOCK OPTION AGREEMENT (Filed With SEC on October 28, 2013)

KARYOPHARM THERAPEUTICS INC. 2013 EMPLOYEE STOCK PURCHASE PLAN October 8, 2013 (Filed With SEC on October 28, 2013)

KARYOPHARM THERAPEUTICS INC. (Filed With SEC on October 28, 2013)

KARYOPHARM THERAPEUTICS INC. THIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT July 26, 2013 (Filed With SEC on October 4, 2013)

KARYOPHARM THERAPEUTICS INC. AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN (Filed With SEC on October 4, 2013)

KARYOPHARM THERAPEUTICS INC. NON-QUALIFIED STOCK OPTION AGREEMENT (Filed With SEC on October 4, 2013)

Consulting Agreement (Filed With SEC on October 4, 2013)

CONSULTING AGREEMENT (Filed With SEC on October 4, 2013)

INDEMNIFICATION AGREEMENT (Filed With SEC on October 4, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH AGREEMENT (Filed With SEC on October 4, 2013)

Category

Industry

Companies

Contracts

Karyopharm Therapeutics Inc. Contracts & Agreements